{"title": "Applying chemical reaction transition theory to predict the latent transmission dynamics of coronavirus outbreak in China", "doi": "10.1101/2020.02.22.20026815", "citation_id": "2020.02.22.20026815v1", "date": "2020-02-25", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.02.22.20026815", "abstract": "<p>The recent outbreak of the Covid-19 suggests a rather long latent phase that precludes public health officials to predict the pandemic transmission on time. Here we apply mass action laws and chemical transition theory to propose a kinetic model that accounts for viral transmission dynamics at the latent phase. This model is useful for authorities to make early preventions and control measurements that stop the spread of a deadly new virus.</p>", "twitter_description": "The recent outbreak of the Covid-19 suggests a rather long latent phase that precludes public health officials to predict the pandemic transmission on time. Here we apply mass action laws and chemical transition theory to propose a kinetic model that accounts for viral transmission dynamics at the latent phase. This model is useful for authorities to make early preventions and control measurements that stop the spread of a deadly new virus.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nBill and Melinda Gates Foundation (OPP1188443)\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nyes, all data is available", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.22.20026815v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.02.22.20026815v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.22.20026815v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/25/2020.02.22.20026815.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NoDerivs 4.0 International), CC BY-ND 4.0, as described at http://creativecommons.org/licenses/by-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.02.22.20026815v1", "access_rights": "restricted", "authors": ["Peng Xu"]}